VYGR SEC Filings - Voyager Therapeutics Inc 10-K, 10-Q, 8-K Forms
This page on Stock Titan provides comprehensive access to Voyager Therapeutics Inc.'s (VYGR) SEC filings, including 10-K, 10-Q, and 8-K reports, along with insider trading forms. It details the company's financial results, corporate updates, pipeline progress in neurological diseases, and collaborations. The platform also offers AI-powered summaries to highlight key information from these regulatory disclosures.
Voyager Therapeutics (NASDAQ:VYGR) CEO Sells $44,547.57 in Stock
Voyager Therapeutics CEO Alfred Sandrock sold 11,511 shares of company stock for $44,547.57 on April 2nd, reducing his ownership by 2.38%. This sale was part of a pre-arranged trading plan and follows earlier sales in February, bringing his year-to-date total to 37,900 shares sold. The company's stock is currently trading near $3.96, with analysts having an average "Moderate Buy" rating and a target price of $16.50.
Voyager Therapeutics (VYGR) CEO sells shares for RSU tax withholding
Voyager Therapeutics President and CEO Alfred Sandrock sold 11,511 shares of common stock at a weighted average price of $3.87 per share. This transaction was not a discretionary trade but occurred under a durable automatic sale instruction to cover tax withholding obligations on restricted stock units (RSUs) that vested on April 1, 2026. Following this sell-to-cover transaction, Sandrock directly holds 472,549 shares of Voyager Therapeutics common stock.
Voyager Therapeutics (VYGR) awards 50,000 RSUs to legal chief
Voyager Therapeutics (VYGR) has granted 50,000 restricted stock units (RSUs) to its SVP and General Counsel, Gregory L. Shiferman, as equity compensation. This award, valued at $0.00 per share, vests over three years, with one-third vesting annually, contingent on continuous service. Following this grant, Shiferman directly holds 50,000 shares/RSUs.
Voyager Therapeutics (NASDAQ:VYGR) Shares Pass Below 50-Day Moving Average - Should You Sell?
Voyager Therapeutics (NASDAQ:VYGR) stock has fallen below its 50-day moving average, trading at $3.96 with a 50-day moving average of $3.92. Despite this technical pullback, analysts maintain a "Moderate Buy" consensus rating with an average price target of $16.50, and institutional investors have increased their positions. Recent insider selling by CEO Alfred Sandrock, however, adds a mixed signal to the company's financial overview, which includes beating Q2 earnings estimates but showing negative net margins and return on equity.
VYGR SEC Filings - Voyager Therapeutics Inc 10-K, 10-Q, 8-K Forms
This page on Stock Titan provides comprehensive access to Voyager Therapeutics Inc.'s (VYGR) SEC filings, including annual reports (10-K), quarterly reports (10-Q), material event filings (8-K), and insider trading forms. It highlights the company's biotechnology focus on neurological diseases, detailing financial figures, pipeline progress (including Alzheimer's programs), and collaboration agreements. The platform also offers AI-powered summaries to help investors quickly parse key information from these regulatory documents.
Voyager Therapeutics (VYGR) price target increased by 12.22% to 17.17
This article reports that the price target for Voyager Therapeutics (VYGR) has been increased by 12.22%, moving it to a new target of $17.17.
Vanguard disaggregates holdings after realignment (VYGR) — reports 0% ownership
Vanguard has filed an amended Schedule 13G/A for Voyager Therapeutics Inc. (VYGR) indicating 0% beneficial ownership and 0 shares. This change follows an internal realignment on January 12, 2026, where certain Vanguard subsidiaries will now report their ownership separately, as per SEC Release No. 34-39538. The filing clarifies that this is an administrative reporting change and not a sale or increase in ownership.
Voyager Therapeutics (NASDAQ:VYGR) Upgraded to Strong-Buy at Truist Financial
Truist Financial has upgraded Voyager Therapeutics (NASDAQ:VYGR) to a "strong-buy" rating, citing recent positive news including a deal that caused a significant stock price increase. Despite beating quarterly earnings and revenue estimates, the company remains unprofitable with a negative net margin. The upgrade contributes to a mixed analyst consensus, with an average target price of $16.50.
Voyager Therapeutics Conference: CEO Calls 2026 “Year of Tau,” Eyes BBB Capsid Clinic Debut
Voyager Therapeutics CEO Al Sandrock declared 2026 the "year of tau," highlighting progress in two tau-directed programs: an antibody and an siRNA-based gene therapy. The company anticipates clinical deployment of its BBB-penetrant capsids in 2026 and plans to share data on a "brain shuttle" platform. Voyager continues to leverage partnerships with Neurocrine, Novartis, and AstraZeneca, retaining potential U.S. opt-in rights and royalties.
Citi Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $11
Citi has reiterated its Buy rating for Voyager Therapeutics (VYGR.US), maintaining a target price of $11. This indicates a continued positive outlook from the firm regarding the company's stock performance.
If You Invested $1,000 in Voyager Therapeutics Inc (VYGR)
This article analyzes the historical performance of investing $1,000 in Voyager Therapeutics Inc (VYGR) over various periods, showing significant losses compared to the S&P 500. It also provides a detailed overview of Voyager Therapeutics Inc, highlighting its focus on gene therapies for neurological diseases like Alzheimer's and Parkinson's, its TRACER™ AAV capsid discovery platform, and its collaborations with other pharmaceutical companies.
Voyager Therapeutics at Stifel 2026 CNS Forum: Year of Tau Focus
Voyager Therapeutics presented its strategic vision at the Stifel 2026 Virtual CNS Forum, focusing on its "year of tau" with ambitious plans to advance tau-targeting assets and novel capsid technology. The company intends to file an IND for its tau knockdown gene therapy in Q2 2026 and aims to demonstrate proof of concept for its capsids and shuttle technology through clinical trials next year. Voyager is pursuing partnerships with major pharmaceutical companies like Neurocrine, Novartis, and AstraZeneca to leverage external expertise and resources for its programs.
Analysts Offer Insights on Healthcare Companies: Merit Medical Systems (MMSI), Voyager Therapeutics (VYGR) and Structure Therapeutics, Inc. Sponsored ADR (GPCR)
Three analysts have issued bullish sentiments on several healthcare companies. Jason Bednar from Piper Sandler maintained a Buy rating on Merit Medical Systems (MMSI) with a $106 price target. Joon Lee from Truist Financial also maintained a Buy rating on Voyager Therapeutics (VYGR), and J.P. Morgan's Hardik Parikh reiterated a Buy rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR).
Analysts Set Expectations for VYGR Q1 Earnings
HC Wainwright has issued its Q1 2027 earnings estimates for Voyager Therapeutics (NASDAQ:VYGR), projecting a loss of ($0.28) per share and maintaining a "Buy" rating with a $25 price target. The company's stock opened at $3.92 and has a market capitalization of $233.63 million, with recent earnings showing a beat on EPS and revenue despite negative net margin and return on equity. Insider selling by CEO Alfred Sandrock contrasts with significant stake increases by institutional investors like AQR Capital Management and Acadian Asset Management, who now collectively own 48.03% of the stock.
Voyager Therapeutics Stock (ISIN: US92916U1025) Eyes Major Upside Amid Gene Therapy Pipeline Momentu
Voyager Therapeutics stock (VYGR) is trading significantly below analyst targets, with a consensus price of $12.96 suggesting over 170% upside from its current $4.65, driven by its advanced AAV gene therapy pipeline for neurological diseases. Despite recent financial losses typical for a clinical-stage biotech and some insider selling, the company's strong institutional ownership and innovative CapsidMap and VectorMap platforms position it for potential breakthroughs in treating conditions like Parkinson's, Huntington's, and ALS. European investors are showing interest due to its availability on Xetra and the growing EU funding for rare neurological diseases.
Is Voyager Therapeutics (VYGR) Balancing Pipeline Ambition With Sustainable Losses After Its 2025 Results?
Voyager Therapeutics (VYGR) reported a smaller net loss for Q4 2025 but a significant increase in its full-year 2025 net loss, widening to US$119.72 million. This highlights the high costs associated with advancing its neurological disease pipeline and the company's continued reliance on financing and partnerships. Ongoing leadership changes, particularly the resignation of the Chief Medical Officer, add to the focus on disciplined clinical execution and the company's ability to manage its losses and achieve forecasted revenues and earnings by 2028.
Is Voyager Therapeutics (VYGR) Balancing Pipeline Ambition With Sustainable Losses After Its 2025 Results?
Voyager Therapeutics (VYGR) reported a reduced net loss for Q4 2025 but a significantly wider full-year net loss, indicating ongoing high costs for its neurological disease pipeline. The company's investment narrative centers on its high-risk pipeline and continued unprofitability, with recent leadership changes and reliance on external partnerships adding to investor considerations. Future financial projections from analysts are optimistic but may need re-evaluation given the recent results and changes.
Guggenheim Remains a Buy on Voyager Therapeutics (VYGR)
Guggenheim analyst Debjit Chattopadhyay reiterated a Buy rating on Voyager Therapeutics (VYGR) with a price target of $22.00, noting the company's shares closed at $5.00 the previous day. The analyst has an 18.4% average return and 49.39% success rate, focusing on the Healthcare sector. Voyager Therapeutics reported a quarterly revenue of $15.34 million and a GAAP net loss of $27.43 million for the quarter ending December 31, and corporate insider sentiment is negative due to increased insider selling.
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Average Recommendation of "Moderate Buy" from Analysts
Voyager Therapeutics (NASDAQ:VYGR) has an average "Moderate Buy" recommendation from analysts, with a target price of $15.00. Insider trading shows sales by the CEO, though institutional investors like EcoR1 Capital have significantly increased their stakes. The company recently surpassed earnings and revenue estimates, reporting -$0.46 EPS against an estimated -$0.54 and $13.46 million in revenue against $10.49 million.
Wells Fargo Sticks to Their Buy Rating for Voyager Therapeutics (VYGR)
Wells Fargo maintained a Buy rating on Voyager Therapeutics (VYGR) and set a price target of $10.00. The company reported increased quarterly revenue of $15.34 million, though insider sentiment is negative with recent share sales. Other analysts also issued ratings for VYGR, with Guggenheim giving a Buy and TipRanks – Google reiterating a Hold.
Voyager Therapeutics Faces Rising Tariff and U.S.–China Geopolitical Risks as BIOSECURE Act Threatens Key Chinese CDMO Partnerships
Voyager Therapeutics (VYGR) is exposed to increased risks due to shifting U.S. and global tariff regimes which could impact input costs and supply chains. The company's reliance on Chinese collaborators is particularly risky due to U.S.-China tensions and the potential impact of the BIOSECURE Act on Chinese Contract Development and Manufacturing Organizations (CDMOs). Wall Street currently holds a Strong Buy consensus rating for VYGR stock.
Earnings Breakdown: Voyager Therapeutics Q4
Voyager Therapeutics (NASDAQ: VYGR) released its Q4 earnings on Monday, March 9, 2026, beating estimated EPS by 11.54% with $-0.46 against an estimate of $-0.52. The company's revenue increased by $9.06 million compared to the previous year. This positive performance follows a trend of beating EPS estimates in prior quarters.
Voyager Therapeutics (VYGR) Q4 Loss Of US$27 Million Reinforces Bearish Profitability Concerns
Voyager Therapeutics (VYGR) reported a Q4 loss of US$27 million and a full-year loss of US$119.7 million, reinforcing bearish concerns about its long-term profitability. While revenue growth trails the broader market, the company's P/S ratio appears cheaper than peers. Investors are urged to consider the ongoing losses and the reliance on future milestones for profitability.
Voyager plans 2026 Alzheimer’s trials, up to $2.4B milestones
Voyager Therapeutics reported its Q4 and full-year 2025 financial results, with a net loss of $119.7 million and collaboration revenue of $40.4 million for the year. The company expects critical clinical milestones in H2 2026, including first-in-human dosing for its tau-silencing gene therapy VY1706 and tau PET imaging data for its anti-tau antibody VY7523 in Alzheimer's disease. Voyager ended 2025 with $201.7 million in cash, projecting a financing runway into 2028, and noted potential milestone payments up to $2.4 billion from partnerships.
Voyager Therapeutics (VYGR) Q4 Loss Of US$27 Million Reinforces Bearish Profitability Concerns
Voyager Therapeutics (VYGR) reported a Q4 basic EPS loss of US$0.47 and a full-year trailing twelve-month net loss of US$119.7 million, alongside revenue growth trailing the broader US market. The company's ongoing unprofitability and expanding losses over multiple years are raising concerns among investors. While some analysts point to pipeline potential, the current financial performance underscores the challenges in achieving profitability, with the stock trading significantly below analyst price targets despite a lower P/S multiple.
Voyager Therapeutics: Fourth Quarter Earnings Overview
Voyager Therapeutics Inc. reported a net loss of $27.4 million, or $0.46 per share, for the fourth quarter, which was better than the anticipated loss of $0.54 per share. The gene therapy firm also surpassed revenue expectations, generating $15.3 million against an anticipated $9.7 million. For the full year, the company had a total loss of $119.7 million and revenues of $40.4 million.
Gene therapy pioneer Voyager Therapeutics Inc (stock code: VYGR) announced that by the end of fiscal year 2025, the company held strong cash and cash equivalents totaling $202 million.
Voyager Therapeutics Inc. (VYGR), a gene therapy company, reported strong cash and cash equivalents of $202 million by the end of fiscal year 2025. This financial position is expected to fund the company's operations and strategic projects until 2028, providing a stable foundation for developing neuroscience therapies. The announcement underscores the company's solid financial health for future R&D activities.
Voyager Therapeutics Q4 2025 Financial Report: Revenue Surpasses Estimates - News and Statistics
Voyager Therapeutics Inc. (VYGR) released its Q4 2025 financial results, reporting a loss of $27.4 million, or 46 cents per share, which was narrower than the 54 cents per share loss predicted by analysts. The company also exceeded revenue forecasts, generating $15.3 million against an anticipated $9.7 million. For the full year 2025, Voyager Therapeutics reported an annual loss of $119.7 million and total annual revenue of $40.4 million.
Voyager Therapeutics reports Q4 2025: $15.3M Q4 collaboration revenue, $119.7M full-year net loss
Voyager Therapeutics announced its Q4 2025 results, reporting $15.3 million in collaboration revenue for the quarter and a net loss of $119.7 million for the full year. The company ended 2025 with $201.7 million in cash, which is expected to fund operations into 2028. Voyager also highlighted upcoming clinical milestones for its tau-targeting programs and NeuroShuttle platform, and progress in its partner programs.
Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
Voyager Therapeutics reported its Q4 and full-year 2025 financial and operating results, highlighting a "transformative year" for its tau-targeting Alzheimer's disease programs and the validation of its brain-targeted capsids. The company expects significant milestones in 2026, including clinical entry for two neuro gene therapies and data readouts for its tau assets. Voyager ended 2025 with $202 million in cash, providing a runway into 2028.
Voyager Therapeutics: Q4 Earnings Snapshot
Voyager Therapeutics Inc. (VYGR) reported a Q4 loss of $27.4 million, or 46 cents per share, which surpassed Wall Street expectations for a 54-cent loss. The gene therapy company also exceeded revenue forecasts, posting $15.3 million against an expected $9.7 million. For the full year, Voyager Therapeutics reported a loss of $119.7 million on revenue of $40.4 million.
Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
Voyager Therapeutics reported its fourth quarter and full year 2025 financial and operating results, highlighting a transformative year for Alzheimer's disease (AD) tau-targeting programs with anticipated clinical entry and data in H2 2026. The company also expects two I.V.-delivered neuro gene therapies to enter the clinic in H2 2026 and ended 2025 with $202 million in cash, providing a runway into 2028. Voyager anticipates significant milestones in 2026, including first-in-human dosing for VY1706 and tau PET imaging data for VY7523 in AD, alongside advancements in its partnerships and nonviral delivery platform.
Gene therapy pioneer Voyager Therapeutics Inc (stock code: VYGR) announced that by the end of fiscal year 2025, the company held strong cash and cash equivalents totaling $202 million.
Voyager Therapeutics Inc. (VYGR), a gene therapy company, concluded fiscal year 2025 with $202 million in cash and cash equivalents. This strong financial position is expected to fund the company's operating expenses and strategic projects until 2028, providing a stable foundation for its innovative neuroscience therapies.
Voyager Therapeutics (VYGR) to Release Quarterly Earnings on Tuesday
Voyager Therapeutics (NASDAQ:VYGR) is scheduled to release its Q4 2025 earnings before the market opens on Tuesday, March 10th. Analysts are anticipating earnings of ($0.54) per share and revenue of $10.4920 million for the quarter. The company will also hold an earnings call on Friday, March 13, 2026, at 5:00 PM ET.
Voyager Therapeutics Touts Tau, Gene Therapy and NeuroShuttle Roadmap, Sees Cash Runway Into 2028
Voyager Therapeutics outlined its strategic roadmap for the year, focusing on three key "pillars of value": advancing two tau-directed programs, initiating two gene therapy clinical entries using blood-brain barrier-penetrant capsids, and expanding its NeuroShuttle brain-delivery platform. The company reported a strong financial position with a cash runway extending into 2028. Voyager highlighted its lead anti-tau antibody VY7523, the gene therapy VY-1706 targeting tau knockdown, and its differentiated NeuroShuttle platform, also noting upcoming clinical entries from partnered programs with Neurocrine.
Voyager Therapeutics (VYGR) CFO executes 4,668-share tax sell-to-cover trade
Voyager Therapeutics' CFO, Nathan D. Jorgensen, conducted a non-discretionary open-market sale of 4,668 shares of common stock at a weighted average price of $3.77 per share. This transaction was a "sell-to-cover" for tax withholding obligations related to the vesting of restricted stock units. Following this disposition, Jorgensen directly holds 151,416 shares of VYGR.
VYGR | Voyager Therapeutics, Inc. Common Financials - Income Statement
This page provides financial information for Voyager Therapeutics, Inc. (VYGR), focusing on its income statement. It includes sections on insider trading, institutional ownership, recent patent grants, and corporate lobbying, alongside a company overview and an emphasis on gene therapy development for neurological diseases.
Voyager Therapeutics (NASDAQ:VYGR) CEO Alfred Sandrock Sells 14,197 Shares
Voyager Therapeutics CEO Alfred Sandrock sold 14,197 shares of the company's stock on February 24th at an average price of $3.79, reducing his stake by 2.85% to 484,060 shares. This transaction follows a previous sale on February 10th. The company's stock is currently trading around $4.13, and analysts have a "Moderate Buy" consensus rating with a wide range of price targets.
Voyager Therapeutics (NASDAQ:VYGR) CFO Sells $17,598.36 in Stock
Voyager Therapeutics (NASDAQ:VYGR) CFO Nathan Jorgensen sold 4,668 shares of company stock for a total of $17,598.36 on February 24th, reducing his holding by 2.99%. The company, a clinical-stage biotechnology firm, has a "Moderate Buy" consensus rating from analysts with an average target price of $13.75. Institutional investors and hedge funds own 48.03% of the stock.
Novartis, Voyager Therapeutics reach license option agreement for next-generation gene therapy vectors for neurological diseases
Novartis has entered into a license option agreement with Voyager Therapeutics for next-generation adeno-associated virus (AAV) capsids to be used in potential gene therapies for neurological diseases. This collaboration aims to overcome challenges in delivering gene therapies to deep brain regions for conditions like central nervous system disorders. The agreement includes upfront payments to Voyager, with additional payments for exercised options, future milestones, and sales-based royalties.
Voyager Therapeutics (VYGR) Form 144: 3,301-share proposed sale; insider sold 3,525
Voyager Therapeutics (VYGR) filed a Form 144, disclosing a proposed sale of 3,301 common shares related to restricted stock vesting on February 17, 2026. This filing also noted a prior sale of 3,525 common shares by Todd Carter on February 10, 2026. The shares involved in the proposed sale are part of compensation and will trade on NASDAQ.
[Form 4] Voyager Therapeutics, Inc. Insider Trading Activity
Voyager Therapeutics, Inc. President and CEO Alfred Sandrock sold 11,732 shares of common stock at a weighted average price of $3.41 per share. The sale was a non-discretionary "sell-to-cover" transaction to satisfy tax obligations related to the vesting of restricted stock units on February 17, 2026, as per a pre-arranged plan adopted on May 12, 2025. Following this transaction, Sandrock directly holds 498,257 shares, indicating his continued substantial equity exposure to the company.
Voyager Therapeutics (NASDAQ:VYGR) Rating Lowered to "Sell" at Wall Street Zen
Wall Street Zen has downgraded Voyager Therapeutics (NASDAQ:VYGR) from a "hold" to a "sell" rating, despite a broader "Moderate Buy" consensus among analysts with an average price target of $13.75 compared to the current trading price of $3.49. Recent insider selling by CEO Alfred Sandrock contrasts with significant institutional buying, such as EcoR1 Capital increasing its stake to over 4 million shares. Voyager Therapeutics is a clinical-stage biotechnology company focusing on gene therapies for neurological diseases, utilizing proprietary platforms for AAV vector development.
EcoR1 discloses 6.8% Voyager Therapeutics (VYGR) ownership stake
EcoR1 Capital and its affiliates have reported a 6.8% ownership stake in Voyager Therapeutics, Inc. (VYGR) common stock through a SCHEDULE 13G/A filing. EcoR1 Capital, LLC and Oleg Nodelman each beneficially own 4,002,847 shares, while EcoR1 Capital Fund Qualified, L.P. holds 3,756,988 shares. The filing indicates the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing control of Voyager Therapeutics.
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Given Average Recommendation of "Moderate Buy" by Brokerages
Voyager Therapeutics (NASDAQ:VYGR) has received an average "Moderate Buy" rating from brokerages, with five buy recommendations and one sell. Analysts have set a mean one-year price target of $13.75 for the stock, which is currently trading near its 52-week lows. Insider selling by CEO Alfred Sandrock and other company insiders has been noted, while institutional investors hold approximately 48.03% of the company's shares.
Voyager Therapeutics Announces Chief Medical Officer Resignation
Voyager Therapeutics (VYGR) announced that its Chief Medical Officer, Toby Ferguson, M.D., Ph.D., resigned effective February 20, 2026, to pursue a new opportunity. President and CEO Alfred W. Sandrock, Jr., M.D., Ph.D. will assume interim medical and strategic responsibilities for the clinical development portfolio. While the company stated the departure was amicable, the interim leadership structure's impact on development initiatives will be observed.
Voyager to Present at Upcoming Investor Conferences
Voyager Therapeutics, Inc. (Nasdaq: VYGR) announced its participation in several upcoming investor conferences in February and March 2026. The biotechnology company, focused on neurological diseases, will engage in fireside chats at events hosted by Guggenheim, Oppenheimer, TD Cowen, Leerink, and Stifel, with a webcast available for the Oppenheimer conference. Voyager specializes in leveraging genetics to treat conditions like Alzheimer’s, Parkinson’s, and ALS, utilizing its TRACER™ AAV capsid discovery platform.
Voyager to Present at Upcoming Investor Conferences
Voyager Therapeutics, Inc. announced its participation in several upcoming investor conferences in February and March 2026. The biotechnology company will hold fireside chats at events such as the Guggenheim Emerging Outlook: Biotech Summit, Oppenheimer 36th Annual Healthcare Life Sciences Conference, TD Cowen 46th Annual Health Care Conference, Leerink Global Healthcare Conference, and Stifel 2026 CNS Days. A webcast of the Oppenheimer fireside chat will be available on Voyager's website.
Biotech Voyager lines up five investor conference talks through March
Voyager Therapeutics (Nasdaq: VYGR) announced it will present at five investor conferences between February and March 2026. These include events hosted by Guggenheim, Oppenheimer, TD Cowen, Leerink, and Stifel. A webcast of the Oppenheimer fireside chat will be available on the company's investors website, with a replay archived for at least 30 days.
